Nintedanib 150mg (Nindanib) 30 Capsules: Label Scope and Dose-Strength Compliance Across Markets

Overview

A single molecule can hold two very different licences, and nintedanib is the clearest example in respiratory and thoracic oncology. The 150mg strength supplied as Nindanib in thirty-capsule packs is the full maintenance dose, and whether it may be sold for fibrosis, for lung cancer, or for both depends entirely on which authority issued the marketing approval in the destination market.

How It Works

Nintedanib blocks three receptor families simultaneously: vascular endothelial growth factor receptors, fibroblast growth factor receptors, and platelet-derived growth factor receptors. In fibrotic lung disease this combined blockade slows fibroblast recruitment and reduces the rate of forced vital capacity decline. In thoracic tumours the same signal interruption starves new vessel formation, which is why the molecule appears in oncology protocols alongside chemotherapy rather than alone. One pharmacology, two regulatory identities, and that duality is what creates the compliance work.

Indications

Idiopathic pulmonary fibrosis is the most widely harmonised approval. Chronic fibrosing interstitial lung disease with a progressive phenotype and systemic sclerosis-associated disease are recognised in many territories but not all. In oncology the licence commonly covers adenocarcinoma histology non-small cell lung cancer after first-line chemotherapy, used together with docetaxel. Product listings that reference small cell disease reflect commercial description rather than uniform registered indication, so buyers should confirm the approved wording locally before promoting it.

Dosage & Administration

The maintenance dose is 150mg twice daily, roughly twelve hours apart, taken with food and swallowed whole without chewing. Where tolerability is limited, the licensed reduction is 100mg twice daily, which is a separate presentation rather than a manipulation of this one. Liver function is checked before starting and at intervals thereafter, and diarrhoea is managed early to protect dose intensity.

Storage & Sourcing

Store below 25°C in the original blister, protected from moisture, and do not repackage into pill organisers because the soft capsules are moisture-sensitive. Two commercial cautions follow. First, thirty capsules cover only fifteen days at maintenance, so monthly demand is two packs per patient. Second, 150mg and 100mg are not interchangeable in dispensing records; stocking both strengths is necessary wherever dose reduction is common.

FAQ

Q: Can a 150mg capsule be split or halved to achieve the reduced dose? No. These are soft gelatin capsules and must be swallowed intact. Dose reduction requires the separately licensed 100mg presentation.

Q: Does an oncology indication in one market permit oncology promotion in another? No. Approval is jurisdiction-specific, and promoting an unapproved indication exposes both distributor and prescriber to enforcement.

Q: Why do product descriptions sometimes mention small cell lung cancer? Marketing copy often broadens beyond the registered wording. Always verify the indication text in the local summary of product characteristics.

Q: What should a buyer check when a pack shows a different strength marking than the invoice? Halt receipt. Strength mismatches between artwork, blister foil and documentation are a recall-level discrepancy, not a clerical one.